Brief: Moberg Pharma Lowers Expectations On Primary Endpoint In Ongoing Trial

Moberg Pharma AB (publ)

13/09/2024 07:09

Sept 13 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * LOWERS EXPECTATIONS ON PRIMARY ENDPOINT IN ONGOING PHASE 3
TRIAL
FOLLOWING DATA IN A SUBSET OF PATIENTS
    * NUMBER OF PATIENTS WHO HAVE ACHIEVED CLINICAL CURE IN THIS
BLINDED SUBSET OF PATIENTS IS LOWER THAN COMPANY'S EXPECTATIONS
    * ASSESSES THAT RISK OF NOT BEING ABLE TO COMMERCIALIZE
PRODUCT IN
US BASED ON THIS STUDY HAS SIGNIFICANTLY INCREASED
    * WILL NOT SPECULATE ON POSSIBLE OUTCOMES OR WHAT THIS MEANS
FOR
FUTURE POTENTIAL OF MOB-015

Source text for Eikon:  ID:nWkr7C7FKD 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))